Home Pharmaceutical europe-bronchiectasis-market

Pharmaceutical

Image

Europe Bronchiectasis Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Europe
  • 350 Pages
  • No of Tables: 440
  • No of Figures: 56

Europe Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe) Industry Trends and Forecast to 2028

Europe Bronchiectasis MarketMarket Analysis and Insights: Europe Bronchiectasis Market

The bronchiectasis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.6% in the forecast period of 2021 to 2028 and is expected to reach USD 250.46 million by 2028. Raising number of alcohol consumers and smokers and technological advancement for disease testing are the major drivers which propelled the demand of the bronchiectasis market in the forecast period.

Bronchiectasis is a term derived from Greek word bronckos which means airways and ectasis means widening. It is a chronic lung condition which is defined as abnormal and irreversible dilation of the bronchi in which both the muscular and elastic tissues are destroyed due to short-term and long-term infection. The combination of these infections leads to one or both lungs damage. The damage site is diagnosed by high resolution computed tomography (HRCT) scan in which it shows that the larger airways are mostly affected and in the smaller airways, the disease are not scanned that’s why some of the patients deals with symptoms for many years before the diagnosis.

The bronchiectasis diagnostics and treatment help critical care patients to provide healthy life which allows patients to save life, this is the reason for the rising patients’ population suffering from bronchiectasis and is acting as the driver for the bronchiectasis market growth. The high cost of diagnostics tools is acting as a restraint for hampering the demand of the bronchiectasis market. The increase in awareness programs for the bronchiectasis is one of the steps that have taken by the organizations and people around the world to minimize the spread of bronchiectasis. These awareness programs can act as an opportunity for the growth of the bronchiectasis market. The complications during the treatment of bronchiectasis act challenging for the healthcare providers which may challenge the bronchiectasis market growth.

The bronchiectasis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the bronchiectasis market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Bronchiectasis MarketBronchiectasis Market Scope and Market Size

The bronchiectasis market is segmented on the basis of the disease type, severity, type, drugs type, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the bronchiectasis market is segmented into CF bronchiectasis and non-CF bronchiectasis. In 2021, non-CF bronchiectasis segment is expected to dominate the bronchiectasis market as it co-exists with other respiratory conditions such as chronic obstructive pulmonary disease (COPD) and is highly prevalent among women and geriatric population.
  • On the basis of severity, the bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the bronchiectasis market because bronchiectasis is a progressive and chronic respiratory disorder which is characterized by persistent cough, abnormally dilated airways, excessive sputum production and recurrent pulmonary infections and all these symptoms are lifelong severe conditions.
  • On the basis of type, the bronchiectasis market is segmented into diagnosis and treatment. In 2021, treatment segment is expected to dominate the bronchiectasis market because patient diagnosed with bronchiectasis have to rely on effective and novel drug therapies so as to lead a normal healthy life.
  • On the basis of drugs type, the bronchiectasis market is segmented into branded and generics. In 2021, branded segment is expected to dominate the bronchiectasis market because drugs offered by the many companies are the patent formulation.
  • On the basis of route of administration, the bronchiectasis market is segmented into oral, parenteral and inhalation. In 2021, inhalation segment is expected to dominate the bronchiectasis market because inhalation route of administration offers effective drug delivery directly to lung airways and increasing technological advancement for launch of smart inhalers that allows patients to maintain accurate drug dosage is also providing market with lucrative growth.
  • On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is dominating the bronchiectasis market because hospitals provides with advanced diagnostic tools used for diagnosis of bronchiectasis associated symptoms.
  • On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is expected to dominate the bronchiectasis market as hospital pharmacy has wide range of products as per the patients need and demand.

Europe Bronchiectasis Market Country Level Analysis

Europe bronchiectasis market is analyzed and market size information is provided on the basis of the country, disease type, severity, type, drugs type, route of administration, end user and distribution channel as referenced above.

The countries covered in the Europe bronchiectasis market report are the Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe.

Non-CF bronchiectasis segment in Europe region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because non-cystic fibrosis bronchiectasis often coexists with other respiratory conditions such as chronic obstructive pulmonary disease. The prevalence of NCFB is increasing, particularly in women and older individuals. Germany is leading the growth of the Europe bronchiectasis market and non-CF bronchiectasis segment is dominating in the region due to rise in prevalence of respiratory diseases. France is the fastest growing country in the Europe region due to rising research and development. The U.K. holds the third largest market share in the European region because of rising government initiatives to create awareness related to the serious respiratory diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Diagnostic Rate and Increasing Healthcare Expenditure are boosting the Bronchiectasis Market Growth

The bronchiectasis market also provides you with detailed market analysis for every country growth in bronchiectasis industry with bronchiectasis drugs sales, impact of advancement in the bronchiectasis technology and changes in regulatory scenarios with their support for the bronchiectasis market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Bronchiectasis Market Share Analysis

The bronchiectasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to bronchiectasis market.

The major companies covered in the Europe bronchiectasis market report are Abbott, HERSILL, Indogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc., Ache Laboratories Farmaceuticos S.A., Horizon Therapeutics plc, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Trudell Medical International, GlaxoSmithKline plc, AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Novartis AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy’s Laboratories Ltd., Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.), Viatris Inc., Covis Pharma, Cipla Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the bronchiectasis market.

For instance,

  • In June 2019, AstraZeneca received approval for Breztri Aerosphere (PT010) in Japan for treatment of COPD. Breztri Aerosphere comprises of budesonide/glycopyrronium/formoterol fumarate and proved as new treatment choice among the people suffering from lung inflammation and other chronic obstructive disease. This approval helped the company to earn constant sales by expanding its product sales across several regions of world.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the bronchiectasis market which also provides the benefit for organization to improve their offering for bronchiectasis.

SKU-

LIST OF TABLES 

TABLE 1 EUROPE BRONCHIECTASIS MARKET, PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 4 THE PRICE OF X-RAY MACHINE

TABLE 5 EUROPE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 6 EUROPE NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 EUROPE CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 EUROPE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 9 EUROPE MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 EUROPE MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 EUROPE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 EUROPE TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 13 EUROPE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 EUROPE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 EUROPE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 EUROPE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 EUROPE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 EUROPE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 EUROPE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 EUROPE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 21 EUROPE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 22 EUROPE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 23 EUROPE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 24 EUROPE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 25 EUROPE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 26 EUROPE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 28 EUROPE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 29 EUROPE BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 EUROPE GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 32 EUROPE INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 EUROPE ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 EUROPE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 EUROPE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 37 EUROPE BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 EUROPE HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 EUROPE HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 EUROPE OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 EUROPE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 EUROPE HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION)

TABLE 44 EUROPE RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 EUROPE ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 EUROPE OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 EUROPE BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION)

TABLE 48 EUROPE BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 49 EUROPE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 50 EUROPE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 51 EUROPE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 EUROPE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 53 EUROPE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 EUROPE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 55 EUROPE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 EUROPE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 EUROPE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 EUROPE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 59 EUROPE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 60 EUROPE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 EUROPE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 EUROPE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 EUROPE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 EUROPE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 EUROPE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 EUROPE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 67 EUROPE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 EUROPE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 EUROPE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 EUROPE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 71 EUROPE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 72 GERMANY BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 73 GERMANY BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 74 GERMANY BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 GERMANY TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 GERMANY TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 GERMANYTREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 GERMANY TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 GERMANY TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 GERMANY TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 GERMANY TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 82 GERMANY TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 GERMANY TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 84 GERMANY TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 85 GERMANY TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 GERMANY TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 87 GERMANY TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 GERMANY DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 GERMANY BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 90 GERMANY BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 GERMANY ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 92 GERMANY PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 93 GERMANY BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 94 GERMANY BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 FRANCE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 FRANCE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 97 FRANCE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 98 FRANCE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 99 FRANCE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 100 FRANCE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 101 FRANCE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 FRANCE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 FRANCE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 FRANCE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 FRANCE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 FRANCE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 FRANCE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 108 FRANCE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 109 FRANCE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 FRANCE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 FRANCE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 112 FRANCE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 113 FRANCE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 114 FRANCE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 115 FRANCE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 116 FRANCE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 117 FRANCE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 118 U.K. BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 119 U.K. BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 120 U.K. BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 U.K. TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 U.K. TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 123 U.K. TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 124 U.K. TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 125 U.K. TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 126 U.K. TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 127 U.K. TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 U.K. TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 129 U.K. TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 130 U.K. TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 U.K. TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 132 U.K. TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 133 U.K. TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 134 U.K. DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 135 U.K. BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 136 U.K. BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 137 U.K. ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 138 U.K. PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 139 U.K. BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 140 U.K. BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 141 ITALY BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 142 ITALY BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 143 ITALY BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 144 ITALY TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 145 ITALY TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 146 ITALY TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 147 ITALY TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 148 ITALY TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 ITALY TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 150 ITALY TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 151 ITALY TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 152 ITALY TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 153 ITALY TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 ITALY TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 ITALY TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 ITALY TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 157 ITALY DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 ITALY BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 159 ITALY BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 160 ITALY ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 161 ITALY PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 162 ITALY BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 163 ITALY BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 164 SPAIN BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 165 SPAIN BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 166 SPAIN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 167 SPAIN TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 168 SPAIN TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 169 SPAIN TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 170 SPAIN TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 171 SPAIN TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 172 SPAIN TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 173 SPAIN TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 174 SPAIN TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 175 SPAIN TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 176 SPAIN TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 177 SPAIN TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 178 SPAIN TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 179 SPAIN TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 SPAIN DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 181 SPAIN BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 182 SPAIN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 183 SPAIN ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 184 SPAIN PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 185 SPAIN BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 186 SPAIN BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 187 NETHERLANDS BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 188 NETHERLANDS BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 189 NETHERLANDS BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 190 NETHERLANDS TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 191 NETHERLANDS TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 192 NETHERLANDS TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 193 NETHERLANDS TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 194 NETHERLANDS TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 195 NETHERLANDS TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 NETHERLANDS TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 197 NETHERLANDS TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 198 NETHERLANDS TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 199 NETHERLANDS TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 200 NETHERLANDS TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 NETHERLANDS TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 202 NETHERLANDS TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 203 NETHERLANDS DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 204 NETHERLANDS BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 205 NETHERLANDS BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 206 NETHERLANDS ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 207 NETHERLANDS PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 208 NETHERLANDS BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 209 NETHERLANDS BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 210 RUSSIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 211 RUSSIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 212 RUSSIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 213 RUSSIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 214 RUSSIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 215 RUSSIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 216 RUSSIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 217 RUSSIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 218 RUSSIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 219 RUSSIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 220 RUSSIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 221 RUSSIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 222 RUSSIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 223 RUSSIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 224 RUSSIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 225 RUSSIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 226 RUSSIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 227 RUSSIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 228 RUSSIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 229 RUSSIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 230 RUSSIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 231 RUSSIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 232 RUSSIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 233 SWITZERLAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 234 SWITZERLAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 235 SWITZERLAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 236 SWITZERLAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 237 SWITZERLAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 238 SWITZERLAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 239 SWITZERLAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 240 SWITZERLAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 241 SWITZERLAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 242 SWITZERLAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 SWITZERLAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 244 SWITZERLAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 245 SWITZERLAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 246 SWITZERLAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 247 SWITZERLAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 248 SWITZERLAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 249 SWITZERLAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 250 SWITZERLAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 251 SWITZERLAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 252 SWITZERLAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 253 SWITZERLAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 254 SWITZERLAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 255 SWITZERLAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 256 BELGIUM BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 257 BELGIUM BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 258 BELGIUM BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 259 BELGIUM TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 260 BELGIUM TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 261 BELGIUM TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 262 BELGIUM TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 263 BELGIUM TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 264 BELGIUM TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 265 BELGIUM TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 266 BELGIUM TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 267 BELGIUM TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 268 BELGIUM TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 269 BELGIUM TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 BELGIUM TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 271 BELGIUM TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 272 BELGIUM DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 273 BELGIUM BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 274 BELGIUM BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 275 BELGIUM ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 276 BELGIUM PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 277 BELGIUM BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 278 BELGIUM BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 279 TURKEY BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 280 TURKEY BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 281 TURKEY BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 282 TURKEY TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 283 TURKEY TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 284 TURKEY TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 285 TURKEY TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 286 TURKEY TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 287 TURKEY TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 288 TURKEY TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 289 TURKEY TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 290 TURKEY TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 291 TURKEY TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 292 TURKEY TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 293 TURKEY TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 294 TURKEY TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 295 TURKEY DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 296 TURKEY BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 297 TURKEY BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 298 TURKEY ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 299 TURKEY PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 300 TURKEY BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 301 TURKEY BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 302 AUSTRIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 303 AUSTRIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 304 AUSTRIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 305 AUSTRIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 306 AUSTRIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 307 AUSTRIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 308 AUSTRIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 309 AUSTRIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 310 AUSTRIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 311 AUSTRIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 312 AUSTRIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 313 AUSTRIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 314 AUSTRIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 315 AUSTRIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 316 AUSTRIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 317 AUSTRIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 318 AUSTRIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 319 AUSTRIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 320 AUSTRIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 321 AUSTRIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 322 AUSTRIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 323 AUSTRIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 324 AUSTRIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 325 NORWAY BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 326 NORWAY BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 327 NORWAY BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 328 NORWAY TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 329 NORWAY TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 330 NORWAY TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 331 NORWAY TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 332 NORWAY TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 333 NORWAY TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 334 NORWAY TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 335 NORWAY TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 336 NORWAY TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 337 NORWAY TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 338 NORWAY TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 339 NORWAY TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 340 NORWAY TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 341 NORWAY DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 342 NORWAY BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 343 NORWAY BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 344 NORWAY ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 345 NORWAY PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 346 NORWAY BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 347 NORWAY BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 348 HUNGARY BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 349 HUNGARY BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 350 HUNGARY BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 351 HUNGARY TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 352 HUNGARY TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 353 HUNGARY TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 354 HUNGARY TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 355 HUNGARY TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 356 HUNGARY TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 357 HUNGARY TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 358 HUNGARY TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 359 HUNGARY TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 360 HUNGARY TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 361 HUNGARY TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 362 HUNGARY TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 363 HUNGARY TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 364 HUNGARY DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 365 HUNGARY BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 366 HUNGARY BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 367 HUNGARY ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 368 HUNGARY PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 369 HUNGARY BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 370 HUNGARY BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 371 LITHUANIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 372 LITHUANIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 373 LITHUANIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 374 LITHUANIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 375 LITHUANIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 376 LITHUANIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 377 LITHUANIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 378 LITHUANIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 379 LITHUANIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 380 LITHUANIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 381 LITHUANIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 382 LITHUANIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 383 LITHUANIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 384 LITHUANIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 385 LITHUANIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 386 LITHUANIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 387 LITHUANIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 388 LITHUANIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 389 LITHUANIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 390 LITHUANIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 391 LITHUANIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 392 LITHUANIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 393 LITHUANIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 394 IRELAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 395 IRELAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 396 IRELAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 397 IRELAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 398 IRELAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 399 IRELAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 400 IRELAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 401 IRELAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 402 IRELAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 403 IRELAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 404 IRELAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 405 IRELAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 406 IRELAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 407 IRELAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 408 IRELAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 409 IRELAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 410 IRELAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 411 IRELAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 412 IRELAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 413 IRELAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 414 IRELAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 415 IRELAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 416 IRELAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 417 POLAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 418 POLAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 419 POLAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 420 POLAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 421 POLAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 422 POLAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 423 POLAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 424 POLAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 425 POLAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 426 POLAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 427 POLAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 428 POLAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 429 POLAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 430 POLAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 431 POLAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 432 POLAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 433 POLAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 434 POLAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 435 POLAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 436 POLAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 437 POLAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 438 POLAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 439 POLAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 440 REST OF EUROPE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

 

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

BROWSE RELATED REPORTS

Global Bronchiectasis Market – Industry Trends and Forecast to 2031
Middle East and Africa Bronchiectasis Market – Industry Trends and Forecast to 2030
Asia-Pacific Bronchiectasis Market – Industry Trends and Forecast to 2028
North America Bronchiectasis Market – Industry Trends and Forecast to 2028
Global Non-Cystic Fibrosis Bronchiectasis Market - Industry Trends and Forecast to 2028
Global Bronchiectasis Market – Industry Trends and Forecast to 2031

BROWSE RELATED Blogs

Global Bronchiectasis Market is growing with 6.0% CAGR in the forecast period of 2021 to 2028
North America Bronchiectasis Market is Growing with 6.1% CAGR in the Forecast Period of 2021 to 2028

BROWSE RELATED Press Release

Rising Number of Smokers and Consumption of Alcohol Drive the Demand for Bronchiectasis Market
AstraZeneca, GlaxoSmithKline Plc and Teva Pharmaceutical Industries Ltd are Dominating the North America Bronchiectasis Market in 2020.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future